<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419482</url>
  </required_header>
  <id_info>
    <org_study_id>2015/468</org_study_id>
    <nct_id>NCT02419482</nct_id>
  </id_info>
  <brief_title>Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training</brief_title>
  <acronym>IMPROV-IT</acronym>
  <official_title>Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool John Moores University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian Catholic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate whether 16 weeks of high intensity interval training, followed by
      36 weeks of home-based exercise, will improve menstrual frequency in women with Polycystic
      Ovary Syndrome (PCOS) compared with a non-exercising control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menstrual frequency</measure>
    <time_frame>1 year</time_frame>
    <description>Electronic menstrual diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Bioimpedance scale and/or DXA, waist circumference, waist/hip-ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Maximal oxygen uptake measured with Oxygon Pro, Jaeger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Flow mediated dilatation of the brachial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>2h oral glucose tolerance test (OGGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima-media thickness</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Ultrasound of the caroid intima-media thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative capacity</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>carbohydrate- and fat oxidation measured with Oxygon Pro, Jaeger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-grade systematic inflammation</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Blood samples and adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue morphology and function</measure>
    <time_frame>16 weeks, (and 36 weeks if funded)</time_frame>
    <description>Adipose tissue biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone profile, blood lipids and blood values</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Systolic and diastolic measured with automatic blood pressure device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Questionnaire (PCOS-specific)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>Physical activity monitor armband (amount and intensity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue mRNA expression</measure>
    <time_frame>16 weeks, (and 36 weeks if funded)</time_frame>
    <description>mRNA analysis of adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ovarian morphology</measure>
    <time_frame>16 weeks, and 36 weeks</time_frame>
    <description>vaginal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>16 weeks , and 36 weeks</time_frame>
    <description>In total, between groups, and among those trying to become pregnant when entering the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>4x4 minutes interval training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x4 minutes high intensity interval training with 4 minute intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10x1 minute interval training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10x1 minute high intensity interval training with 1 minute intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Physical activity recommended</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>4x4 minutes high intensity interval training</intervention_name>
    <description>Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.</description>
    <arm_group_label>4x4 minutes interval training</arm_group_label>
    <other_name>High-intensity exercise</other_name>
    <other_name>Aerobic exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>10x1 minute high intensity interval training</intervention_name>
    <description>Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.</description>
    <arm_group_label>10x1 minute interval training</arm_group_label>
    <other_name>High-intensity exercise</other_name>
    <other_name>Aerobic exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Polycystic ovary syndrome (PCOS) according to the Rotterdam criteria

        Exclusion Criteria:

          -  Regular high intensity endurance (two or more times per week of vigorous exercise).

          -  Concurrent treatments (insulin sensitizers or drugs known to affect gonadotropin or
             ovulation, with a wash out period of 1 months prior to inclusion).

          -  On-going pregnancy.

          -  Breast feeding within 24 weeks

          -  Cardiovascular disease or endocrine disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trine Moholdt, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ida Almenning</last_name>
    <email>ida.almenning@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trine Moholdt, phd</last_name>
    <email>trine.moholdt@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre of Exercise and Nutrition, Mary MacKillop Institute for Health Research, AUC</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Lionett, M.Sc</last_name>
      <email>sofie.b.lionett@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>John Hawley</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of circulation and medical imaging , NTNU</name>
      <address>
        <city>Trondheim</city>
        <zip>7491</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Almenning</last_name>
      <phone>0047 97032036</phone>
      <email>ida.almenning@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>Trine Moholdt, phd</last_name>
      <phone>0047 97098594</phone>
      <email>trine.moholdt@ntnu.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise therapy</keyword>
  <keyword>Reproductive Physiological Processes</keyword>
  <keyword>Fertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

